Substances
Mesembrine — Compound Profile
Mesembrine 2D structure of Mesembrine (C17H23NO3) — source: PubChem CID 394162 Chemistry CID: 394162 · PubChem Formula: C17H23NO3 Molecular weight: 289.4 g/mol IUPAC: (3aS,7aS)-3a-(3,4-dimethoxyphenyl)-1-methyl-2,3,4,5,7,7a-hexahydroindol-6-one CAS: 24880-43-1 Family & pharmacology Family: Sceletium alkaloid (mesembrane-type tricyclic) Pharmacological class: Serotonin reuptake inhibitor (SRI) and phosphodiesterase type 4 (PDE4) inhibitor. Mesembrine inhibits the serotonin transporter (SERT) with potency comparable to SSRIs, increasing synaptic serotonin availability. The concurrent PDE4 inhibition — which raises intracellular cAMP — is a mechanistic feature not found in conventional SSRIs and may contribute to anxiolytic and cognitive effects observed in preclinical and clinical studies. Mesembrine does not exhibit monoamine oxidase inhibition at relevant concentrations. Natural source: Mesembrine is the primary alkaloid in Sceletium tortuosum (kanna), a small succulent plant native to the semi-arid regions of South Africa, particularly the Western Cape and Northern Cape provinces. The plant contains at least four major alkaloids (mesembrine, mesembrenone, mesembrenol, and mesembranol); mesembrine typically predominates in fermented preparations (called kougoed). Total alkaloid content varies significantly between chemotypes and growing conditions. Historical context Sceletium tortuosum has one of the longest documented histories of use of any psychoactive plant. The earliest written account was by Jan van Riebeeck, the Dutch VOC commander who established the Cape Colony, who recorded Khoisan use of kanna in his diary in 1662. Subsequent colonial-era accounts describe kanna as a valuable trade commodity between Khoisan groups, sometimes used in lieu of tobacco or exchanged for livestock. Mesembrine as an alkaloid was first isolated in 1898 by German pharmacologists Bodendorf and Krieger from dried Sceletium material. Its full chemical structure was elucidated over the following decades, with the mesembrane carbon skeleton fully described by the mid-20th century. Modern pharmacological characterisation of its serotonergic mechanism was established in the 1990s. Traditional use Khoisan and early Cape Coloured communities chewed, smoked, or used fermented kanna (kougoed) as snuff for mood elevation, sociality, and pain relief Hunters used kanna to suppress hunger and thirst on long treks; it was also used for toothache and intestinal complaints Kanna functioned as an important trade good between Khoisan groups across the Cape, sometimes commanding high barter value Fermentation (kougoed preparation) involved burying plant material and allowing it to ferment over days, which transforms alkaloid ratios — increasing mesembrenone relative to mesembrine and affecting potency Modern research context Scientific interest in mesembrine and Sceletium extracts accelerated from the 2000s. The commercial extract Zembrin® (a standardised 2:1 extract of Sceletium tortuosum) has been evaluated in multiple clinical studies. Harvey et al. published the first randomised controlled trial in humans in 2011 (J Ethnopharmacol 2011, PMID 22234675), demonstrating anxiolytic effects and improved cognitive flexibility in healthy volunteers. A subsequent randomised double-blind crossover trial (Nell et al. 2013) found that Zembrin attenuated threat-related amygdala reactivity in healthy subjects — a finding consistent with anxiolytic activity. The dual SRI+PDE4 mechanism distinguishes mesembrine from classic SSRIs, and its relatively rapid onset of effect (hours rather than weeks, as reported in qualitative user accounts) has been a subject of mechanistic interest. PDE4 inhibition alone (as seen in roflumilast) has antidepressant-like effects in animal models, potentially synergising with SERT blockade. Safety Mesembrine and Sceletium tortuosum preparations are generally considered to have a benign safety profile at low-to-moderate doses. Reported adverse effects include mild headache, nausea, and initial sedation. The most significant pharmacological interaction risk is with other serotonergic agents: co-administration of Sceletium preparations with SSRIs, SNRIs, or MAOIs raises the theoretical risk of serotonin syndrome and should be avoided. Case reports of serotonin syndrome with kanna have appeared in the literature. Sceletium has no meaningful cardiovascular or hepatotoxic risk profile at doses used traditionally or in clinical studies. It is not considered habit-forming in the classical sense, though tolerance and mild psychological dependence are plausible with regular high-dose use. It is not recommended during pregnancy or lactation in the absence of safety data. Legal status in Germany As of 2026, mesembrine and Sceletium tortuosum are not scheduled in the German Narcotics Act (BtMG, Anlagen I–III) or the New Psychoactive Substances Act (NpSG). The plant, its extracts, and mesembrine as an isolated alkaloid are legal to possess, sell, and purchase in Germany. Kanna and Sceletium extracts are openly available in health supplement and botanical retail channels in Germany and the EU. Related content Plant Extracts at amama Mitragynine — Compound Profile Muscimol — Compound Profile
Learn moreMuscimol — Compound Profile
Muscimol 2D structure of Muscimol (C4H6N2O2) — source: PubChem CID 4266 Chemistry CID: 4266 · PubChem Formula: C4H6N2O2 Molecular weight: 114.1 g/mol IUPAC: 5-(aminomethyl)-1,2-oxazol-3-one CAS: 2763-96-4 Family & pharmacology Family: Isoxazole (not an indole alkaloid) Pharmacological class: GABA-A receptor full agonist — binds selectively and potently at the GABA-binding site (orthosteric site) of GABA-A receptors, producing sedative, hypnotic, anxiolytic, and at higher doses dissociative/psychedelic effects. Unlike benzodiazepines (which act allosterically), muscimol is a direct agonist and therefore active even in the absence of endogenous GABA. It does not act on serotonergic (5-HT₂A) or dopaminergic pathways. Natural source: Muscimol is the primary psychoactive constituent of Amanita muscaria (fly agaric) and related Amanita species including A. pantherina and A. regalis. It is formed in vivo and during drying/cooking by decarboxylation of ibotenic acid, a structural precursor also present in fresh fruiting bodies. The ratio of ibotenic acid to muscimol is highly variable and depends on drying temperature and time. Historical context Muscimol was first isolated in 1964 by Swiss chemist Conrad Hans Eugster and colleagues at the University of Zurich, who also elucidated its structure and confirmed its GABAergic mechanism. Interest in Amanita muscaria as a psychoactive agent long predates isolation: ethnomycologist R. Gordon Wasson proposed in 1968 (Soma: Divine Mushroom of Immortality) that fly agaric was the identity of Soma, the sacred beverage described in the Rigveda — a hypothesis that remains debated among ethnobotanists and classicists. Siberian and Eurasian accounts of fly agaric use — particularly among Koryak, Chukchi, and Evenki reindeer herders — were documented by European travellers from the 18th century onward. The anthropologist Jochen Gartz and others have argued that the reindeer–Amanita relationship (reindeer actively seeking fly agaric) has contributed to shamanic iconography including the Santa Claus myth. Traditional use Siberian shamanic ritual: fly agaric dried and consumed by shamans to induce visionary states; urine recycling (muscimol is excreted largely unchanged) was documented in several ethnohistorical sources Reindeer herding communities in northeastern Siberia consumed fly agaric to reduce fatigue and pain on long journeys Not documented in significant traditional use contexts in Central or Western Europe, despite widespread occurrence of A. muscaria Modern research context Contemporary research interest in muscimol centres on its GABA-A agonism as a tool compound to map receptor subunit specificity, and on potential therapeutic applications in anxiety and epilepsy. Muscimol's selectivity profile differs from benzodiazepines and barbiturates, and unlike many GABA-A modulators it does not require a specific subunit combination, making it a useful research probe. Muscimol shows anticonvulsant effects in animal models and has been investigated for neuroprotective properties in ischemia models. It is important to note that muscimol has no serotonergic activity — its experiential profile (sedation, dreamlike states, body effects) differs substantially from classical psychedelics (psilocybin, LSD). Clinical research in humans remains limited; most data derive from animal pharmacology. Safety Muscimol is potent at low doses (effective dose range reported in the single-digit milligram range in experienced users). Fresh Amanita muscaria fruiting bodies contain predominantly ibotenic acid, which must be converted to muscimol by decarboxylation (typically via controlled drying at 50–70 °C). Ibotenic acid is a neuroexcitatory NMDA receptor agonist that contributes to nausea and dysphoria. Improperly prepared material therefore carries higher risk than preparations where decarboxylation is complete. Dose–response is steep and highly variable between specimens. Adverse effects include nausea, vomiting, excessive salivation, confusion, and ataxia. There is no specific antidote; supportive care is standard. Combining muscimol with alcohol or other CNS depressants significantly increases the risk of respiratory depression. Not appropriate for unsupervised use. Legal status in Germany As of 2026, muscimol is not scheduled in the German Narcotics Act (BtMG, Anlagen I–III) and is not listed in the New Psychoactive Substances Act (NpSG). Amanita muscaria mushrooms and muscimol-containing preparations are legal to possess, purchase, and sell in Germany. There is no medicinal-use restriction comparable to that affecting ibogaine or psilocybin. Amanita muscaria extracts and dried fruiting bodies are openly traded as botanical specimens. Related content Plant Extracts at amama Ibogaine — Compound Profile Mitragynine — Compound Profile
Learn moreIbogaine — Compound Profile
Ibogaine 2D structure of Ibogaine (C20H26N2O) — source: PubChem CID 197060 Chemistry CID: 197060 · PubChem Formula: C20H26N2O Molecular weight: 310.4 g/mol IUPAC: (1R,15R,17S,18S)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene CAS: 83-74-9 Family & pharmacology Family: Indole alkaloid (ibogamine-type) Pharmacological class: NMDA receptor antagonist; kappa-opioid receptor agonist; sigma-2 receptor agonist; serotonin transporter inhibitor (SERT); nicotinic acetylcholine receptor antagonist. Preclinical data also indicate upregulation of BDNF (brain-derived neurotrophic factor), which may underlie reported neuroplastic effects in animal models. Natural source: Ibogaine is the principal psychoactive alkaloid in the root bark of Tabernanthe iboga, a perennial understory shrub native to the rainforests of Gabon, Cameroon, and the Republic of Congo. The root bark contains a complex of 12 or more iboga alkaloids; ibogaine typically constitutes 10–20 % of total alkaloid content. Historical context Ibogaine was first isolated in 1901 by French pharmacologists Dybowski and Landrin from Tabernanthe iboga, two years after iboga root bark was exhibited at the Paris Exposition. Its full chemical structure was determined in 1958, followed by the first total synthesis by Büchi et al. (J. Am. Chem. Soc. 1958). Western pharmaceutical interest peaked in the 1960s when it was briefly marketed in France as Lambarène — a stimulant tonic — before being withdrawn from the market. Modern addiction-interruption research traces to self-experimenter Howard Lotsof, who in 1962 observed that a single session appeared to interrupt his heroin use and filed the first treatment patents in the 1980s. Alper et al. (Alkaloids 1999, PMID 10332749) published a systematic review of 33 cases, establishing ibogaine's profile in the clinical literature. Traditional use — Bwiti ceremony Central to the Bwiti initiation rite of the Mitsogo and Fang peoples of Gabon and Cameroon, where large doses of root bark are consumed over multi-day initiation ceremonies Considered a sacrament that enables contact with ancestral spirits; the full initiatory dose is taken once in a lifetime in traditional contexts Smaller doses are used in ongoing Bwiti ritual practice, notably as a collective stimulant during all-night ceremonies (ngoze) Listed as part of the UNESCO-recognized Bwiti intangible cultural heritage of Gabon (2008) Modern research context Contemporary clinical interest centres on ibogaine's reported ability to reduce opioid withdrawal symptoms and craving in a single session. Noller et al. (Subst Abuse 2018, PMID 29869598) found significant reductions in opioid use scores 12 months after treatment in a New Zealand open-label study (n=14). A Stanford retrospective (Nat Med 2023, PMID 36905680) of military veterans reported substantial reductions in PTSD, depression, and anxiety scales. Mechanistically, the multi-receptor profile — including BDNF upregulation, NMDA antagonism, and kappa-opioid activity — distinguishes ibogaine from single-target pharmacotherapies. It is actively investigated at MAPS, NYU, and the Universidade Federal Fluminense. Safety Ibogaine carries a well-documented cardiac risk: QT interval prolongation that can trigger fatal ventricular arrhythmia (Torsades de Pointes). Litjens & Brunt (Regul Toxicol Pharmacol 2016, PMID 26284997) reviewed 19 ibogaine-related fatalities; most involved pre-existing cardiac conditions or concomitant substances. Medical screening (ECG, electrolytes) and cardiac monitoring during administration are considered standard of care in clinical research settings. Ibogaine is not suitable for self-administration. Legal status in Germany Ibogaine is not listed in the Narcotics Act (BtMG, Anlagen I–III) or the New Psychoactive Substances Act (NpSG) as of 2026. Possession and purchase of the compound are not prohibited under substance law. However, ibogaine has no medicinal approval (Arzneimittelgesetz / AMG), meaning it cannot be prescribed or administered therapeutically by healthcare providers in Germany. The distinction between legal possession and unlicensed medical use is critical. See the full analysis in Iboga Legal Status in Germany & Europe 2026. Related content Iboga Guide: The Complete Plant Profile Iboga Effects: Pharmacology & Mechanism of Action Ibogaine Therapy in Europe: Clinics & Research Iboga Legal Status in Germany & Europe 2026
Learn moreMitragynine — Compound Profile
Mitragynine 2D structure of Mitragynine (C23H30N2O4) — source: PubChem CID 3034396 Chemistry CID: 3034396 · PubChem Formula: C23H30N2O4 Molecular weight: 398.5 g/mol IUPAC: methyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate CAS: 4098-40-2 Family & pharmacology Family: Indole alkaloid (corynantheidine-type) Pharmacological class: Partial agonist at mu-opioid receptors with additional activity at delta- and kappa-opioid receptors; also reported to interact with adrenergic and serotonergic systems in preclinical studies Natural source: Mitragynine is the most abundant alkaloid in the leaves of Mitragyna speciosa (kratom), a tree in the coffee family (Rubiaceae) native to Southeast Asia, particularly Thailand, Malaysia, Indonesia, Myanmar, and Papua New Guinea Historical context Mitragynine was first isolated in 1907 by Dutch botanist E. M. Field from Mitragyna speciosa leaves, with its structure fully elucidated by Zacharias in 1964. The compound has been studied extensively as the primary alkaloid responsible for kratom's traditional effects, though 7-hydroxymitragynine (a minor alkaloid) has been shown in later research to be substantially more potent at mu-opioid receptors. Traditional use Chewed fresh or brewed as tea by laborers in southern Thailand and Malaysia to sustain work through heat and fatigue Used in traditional Southeast Asian folk medicine for management of pain, cough, and diarrhea Served in social and ceremonial contexts in rural Malay and Thai communities, sometimes as a substitute when other substances were scarce Modern re-emergence From the 2010s onward, kratom (and by extension mitragynine) became widely discussed in Western harm-reduction and self-management contexts, particularly in the United States. Regulatory status varies significantly by country: kratom is controlled in Thailand historically (now partially decriminalized since 2021), Australia, and several EU states, while remaining legal in others. Mitragynine as an isolated alkaloid is the subject of ongoing pharmacological research into analgesic mechanisms with reduced respiratory depression compared to classical opioids. Safety Documented adverse effects of kratom use include nausea, vomiting, constipation, tachycardia, and with chronic high-dose use, dependence and withdrawal syndromes. Case reports have described hepatotoxicity and seizures, often in the context of polysubstance use. Mitragynine is metabolized by CYP3A4 and CYP2D6; co-use with other serotonergic or opioid compounds, MAOIs, or strong CYP inhibitors has been associated with adverse interactions in case literature. Not recommended during pregnancy or with pre-existing liver conditions. 🏪 amama POV Sourcing: amama sources kratom leaf powder directly from established partner farms in Indonesia (predominantly West Kalimantan and Sumatra), where the trees grow in their native habitat and leaves are harvested and dried using traditional methods. We do not sell isolated mitragynine — only whole-leaf kratom powder in which mitragynine occurs naturally alongside the full alkaloid spectrum. Quality measures Every batch is lab-tested for pesticides, heavy metals (lead, cadmium, arsenic, mercury) and microbiology (Salmonella, E. coli, yeast/mould) Alkaloid profiling available on request — typical mitragynine content documented per batch Certificate of Analysis (CoA) available on request Sealed, opaque packaging to protect alkaloids from UV and oxidation; batch and lot codes on every package for traceability No blends with synthetic enhancers or undisclosed additives — single-strain, single-origin powder only Experience: amama has carried kratom since 2021 and it is one of the categories our team knows most intimately. Because we run two physical stores in Berlin-Neukölln in addition to the online shop, the team has in-person conversations about kratom every single day — strain differences, onset, tolerance dynamics, tapering — qualitative depth that purely online sellers simply don't see. Customer feedback: Questions we hear in the store regularly are around strain differentiation (red vs. green vs. white), rotation to avoid tolerance, and comparisons between batches of the same strain. Customers tell us in person that batch-to-batch consistency and the ability to ask follow-up questions are the main reasons they return — feedback that rarely shows up in short online reviews. Sources PubChem CID 3034396 Wikipedia: Mitragynine; Mitragyna speciosa Kruegel & Grundmann 2018, Neuropharmacology — 'The medicinal chemistry and neuropharmacology of kratom' Hassan et al. 2013, Neuroscience & Biobehavioral Reviews Warner et al. 2016, International Journal of Legal Medicine EMCDDA kratom drug profile Prozialeck et al. 2012, Journal of the American Osteopathic Association
Learn moreApomorphine — Compound Profile
Apomorphine 2D structure of Apomorphine (C17H17NO2) — source: PubChem CID 6005 Chemistry CID: 6005 · PubChem Formula: C17H17NO2 Molecular weight: 267.32 g/mol IUPAC: (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol CAS: 58-00-4 Family & pharmacology Family: Aporphine alkaloid (semi-synthetic derivative of morphine) Pharmacological class: Non-selective dopamine receptor agonist (D1/D2 family); structurally part of the aporphine class, though apomorphine itself is produced by acid-catalysed rearrangement of morphine rather than isolated from plants Natural source: Apomorphine is not found in meaningful quantities in nature; it is synthesised from morphine (derived from Papaver somniferum). It is often mentioned in discussions of Nymphaea caerulea (blue lotus) because the plant contains related aporphine-type alkaloids such as nuciferine, and because secondary literature (e.g. Ancient Origins) has proposed apomorphine-like activity as part of the flower's historical psychoactive reputation. This attribution remains debated in the botanical literature. Historical context Apomorphine as a molecule belongs to the 19th- and 20th-century history of pharmacology: first prepared in 1845 by Arppe and developed further by Matthiessen and Wright in the 1860s through acid treatment of morphine. Its cultural footprint, however, is often discussed alongside the far older ritual use of Nymphaea caerulea in ancient Egypt, where aporphine-class alkaloids are thought to contribute to the flower's reported effects. Traditional use Referenced in the context of Nymphaea caerulea ritual use documented on tomb frescoes such as the Tomb of Nebamun (Dynasty XVIII, Thebes) and the gold-plated shrine of Tutankhamun, where the pharaoh is shown holding a giant Nymphaea alongside two mandragoras (Ancient Origins; Bertol et al. 2004) The Ebers Papyrus (c. 1500 BC) and the Egyptian Book of the Dead describe blue lotus in medicinal and magico-religious contexts — as aphrodisiac, for pain, for insomnia and for settling the stomach — traditional attributions, not modern medical claims 19th-century European medicine used apomorphine itself as a powerful emetic and later in aversion therapy for alcohol dependence — part of the compound's own history, separate from the Egyptian plant context Modern re-emergence Apomorphine re-emerged in late 20th-century neurology as a licensed treatment for advanced Parkinson's disease (motor fluctuations), and in the early 2000s was marketed under names such as Ixense and Uprima for erectile dysfunction (Ancient Origins; clinical literature). Academic interest in Nymphaea caerulea's aporphine alkaloids — distinct from apomorphine proper — continues in ethnopharmacology (Bertol et al. 2004; Haddad 2021). Safety Apomorphine is a prescription-only medicine in Germany and the EU. It is associated with significant side effects including nausea and vomiting (often requiring antiemetic co-administration), orthostatic hypotension, somnolence, QT-interval effects and, in Parkinson's use, impulse-control disorders. It is not a recreational or smartshop substance and should only be used under medical supervision. Information here is educational only. amama POV Sourcing: amama does not sell apomorphine. It is a prescription pharmaceutical regulated under the German Arzneimittelgesetz and is not part of our ethnobotanical or research-chemical range. We include this profile only as educational context, because customers reading about Nymphaea caerulea often encounter apomorphine in secondary sources. Quality measures Not stocked — no sourcing, no batch, no CoA: apomorphine is a pharmacy-dispensed medicine and outside amama's scope For the related plant Nymphaea caerulea that amama does sell, every batch is lab-tested for pesticides, heavy metals and microbiology Blue lotus is sourced from established partner farms in Egypt and Thailand with full batch traceability CoAs available on request for all botanical products we carry We deliberately separate pharmaceutical compounds like apomorphine from the botanicals we offer, and we flag this distinction to customers who ask Experience: amama has operated two physical stores in Berlin plus the online shop at amama.space since 2021, and blue lotus has been part of the range from the start. Because the team speaks with customers in person every day, we regularly encounter questions about apomorphine and aporphine alkaloids that never show up in online reviews — a qualitative signal online-only sellers simply do not have access to. Customer feedback: Questions we hear in the Neukölln store regularly are whether blue lotus 'contains apomorphine' — a claim customers often bring in from online articles. Our standard in-store answer is that Nymphaea caerulea contains aporphine-class alkaloids such as nuciferine, while apomorphine itself is a pharmaceutical derivative of morphine, and that the two should not be conflated. Explore further Blue Lotus — the complete guide — pillar article on what blue lotus actually contains and how it was used historically Nuciferine — Compound Profile — the primary aporphine alkaloid present in blue lotus Blue Lotus at amama — whole flower, tinctures and extracts, lab-tested Sources PubChem CID 6005 — Apomorphine Wikipedia — Apomorphine Ancient Origins — Blue Lotus: The Ancient Egyptian Dream Flower Bertol, E., Fineschi, V., Karch, S. B., et al. (2004). Nymphaea cults in ancient Egypt and the New World. Journal of the Royal Society of Medicine, 97(2), 84–85. Haddad, C. G. (2021). Uppsala University thesis on ritualistic use of Nymphaea European Medicines Agency — apomorphine product information
Learn moreNuciferine — Compound Profile
Nuciferine 2D structure of Nuciferine (C19H21NO2) — source: PubChem CID 10146 Chemistry CID: 10146 · PubChem Formula: C19H21NO2 Molecular weight: 295.4 g/mol IUPAC: (6aR)-1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline CAS: 475-83-2 Family & pharmacology Family: Aporphine alkaloid Pharmacological class: Dopamine receptor modulator (documented D2 antagonist activity); also reported interactions with serotonin (5-HT2A) and adrenergic receptors in in-vitro studies Natural source: Occurs primarily in the leaves and flowers of Nymphaea caerulea (Egyptian blue lotus) and Nelumbo nucifera (sacred lotus). Present alongside related aporphines such as apomorphine and nornuciferine. Historical context Nuciferine is one of the principal alkaloids in Nymphaea caerulea, the blue water lily that played a central role in ancient Egyptian religious, funerary and symbolic life. Though the compound itself was only isolated and characterised in the 20th century, the plant containing it has one of the longest continuous documented ceremonial records of any psychoactive botanical, stretching from Pharaonic Egypt through classical antiquity into modern ethnobotany. Traditional use Referenced in the Ebers Papyrus (c. 1500 BC), one of the oldest surviving medical texts, among roughly 800 botanical recipes of ancient Egypt (Ancient Origins; Bertol et al. 2004). Depicted in the Egyptian Book of the Dead and in the Book of the Dead of Hunefer as part of afterlife and rebirth imagery — the flower's daily cycle (opening around 9:30 AM, closing around 3:00 PM) mirrored the solar journey and became a symbol of resurrection. Found in Tutankhamun's tomb on a gold-plated shrine showing the pharaoh holding a giant Nymphaea alongside two mandragora fruits, a pairing that has been interpreted as evidence of deliberate combination of psychoactive botanicals (Bertol et al. 2004). Shown in the Tomb of Nebamun (Dynasty XVIII, Thebes; British Museum) in ritual dance and banquet scenes, with garlanded women and vases emitting 'golden emanations', and in the Turin Papyrus in the context of temple wine cults restricted to priests and royalty. Historically attributed with aphrodisiac properties and traditional use for pain, low mood, anxiety, digestive upset and sleeplessness — these are historical attributions, not modern medical claims. Modern re-emergence Nuciferine was isolated from Nelumbo nucifera in the early-to-mid 20th century and has since been studied in pharmacological research for its dopamine D2 antagonist profile, with additional published work exploring serotonergic binding and metabolic effects. Interest in Nymphaea caerulea preparations has grown again through the ethnobotanical and smartshop scene in Europe, where the flower is sold as a traditional botanical rather than a pharmaceutical product. Safety Pharmacological literature (PubChem, published in-vitro studies) describes nuciferine as a dopamine D2 antagonist with additional receptor activity; this profile suggests a meaningful potential for interaction with dopaminergic, serotonergic and antipsychotic medications. Data on isolated nuciferine in humans is limited — most human experience is with whole Nymphaea caerulea flower preparations, where alkaloid content varies between batches. Combinations with other CNS-active substances are not well characterised. Not suitable during pregnancy, breastfeeding, or alongside psychiatric medication without professional guidance. amama POV Sourcing: amama does not sell isolated nuciferine. The compound reaches our customers exclusively through whole Nymphaea caerulea flower, sourced from established partner farms in Egypt and Thailand where the plant has a long cultivation history. We focus on whole-flower and properly dried petal material rather than concentrated alkaloid extracts. Quality measures Every batch of blue lotus flower is lab-tested for pesticides, heavy metals and microbiological load before it reaches the shelf Certificate of Analysis available on request for each batch Visual and organoleptic checks on arrival — intact petals, characteristic colour, clean aroma — before the batch is released Stored cool, dark and dry in sealed packaging to protect the alkaloid fraction (including nuciferine and apomorphine) from oxidation and UV degradation Batch traceability from partner farm to store shelf, so any lot can be tracked back to its origin harvest Experience: amama has carried blue lotus since 2021 across both Berlin stores and amama.space. Because we operate two physical shops in Neukölln, the team hears real-time qualitative feedback in person every day — depth that online-only sellers simply do not have access to through short reviews and emails. Customer feedback: Customers tell us in the store that blue lotus is most often used as a gentle evening tea or in tinctures, and the questions we hear in person regularly are about combining it with cannabis or wine (historical Egyptian pairing) and about the difference between whole flower and concentrated extracts — nuances that almost never show up in written reviews. Explore further Blue Lotus — the complete guide — pillar article on effects, history and sourcing Apomorphine — Compound Profile — the related aporphine alkaloid, often confused with nuciferine Blue Lotus at amama — whole flower, tinctures and extracts, lab-tested Sources PubChem CID 10146 — Nuciferine Wikipedia — Nuciferine Wikipedia — Nymphaea caerulea Ancient Origins — Blue Lotus: The Ancient Egyptian Dream Flower Bertol, E., Fineschi, V., Karch, S. B., et al. (2004). Nymphaea cults in ancient Egypt and the New World. Journal of the Royal Society of Medicine, 97(2), 84–85. Ebers Papyrus (c. 1500 BC, primary historical source) Farrell, M. S., McCorvy, J. D., Huang, X.-P., et al. (2016). In vitro and in vivo characterization of nuciferine. PLOS ONE, 11(3), e0150602. Haddad, C. G. (2021). Uppsala University thesis on ritualistic use Hammond, C. (2021). Blue Lotus: The Ancient Egyptian Dream Flower
Learn moreA Chronicle of LSD Analogues in Germany
Current Status: 1S-LSD Legal (October 2025) – Not yet formally prohibited by the Narcotics Act or the New Psychoactive Substances Act (NpSG). Germany's approach to psychedelic substances reflects a complex interplay between public health concerns, scientific advancement, and evolving cultural attitudes toward consciousness-altering compounds.
Learn more